Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
64.78
-0.55 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
October 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
October 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 12, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
5 Reasons Gilead Sciences is a Better Buy Than You Think
October 10, 2023
Gilead Sciences is a value and high-yielding stock on the brink of a stock rebound that could add double-digits to investors portfolios this year an next.
Via
MarketBeat
Exposures
COVID-19
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
October 05, 2023
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
October 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
October 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Inc. (NASDAQ: GILD) Making Surprising Moves in Tuesday Session
September 26, 2023
Via
Investor Brand Network
Exposures
COVID-19
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
September 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
September 18, 2023
Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains.
Via
MarketBeat
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
September 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Exposures
Product Safety
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
September 10, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Prices $2 Billion of Senior Unsecured Notes
September 07, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
August 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
August 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
August 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
August 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
August 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Hypertrophic Cardiomyopathy Therapeutics Market Projected to Show Strong Growth : Novartis, Gilead Sciences, ADVANZ PHARMA
August 08, 2023
Stay up-to-date with Hypertrophic Cardiomyopathy Therapeutics Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Gilead Sciences Announces Second Quarter 2023 Financial Results
August 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
7 Best Cancer Stocks to Invest in Now
July 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Via
MarketBeat
Topics
Death
Exposures
Death
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
July 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
July 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
July 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
July 20, 2023
From
The Center for Disease Analysis Foundation
Via
Business Wire
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
July 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
July 20, 2023
From
CDA Foundation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.